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Abstract
Lipopolysaccharide (LPS) from the cell envelope of Gram-negative bacteria is a principal
cause of the symptoms of sepsis. LPS has been reported to modulate the function of plate-
lets although the underlying mechanisms of LPS action in these cells remain unclear. Plate-
lets express the Toll-like receptor 4 (TLR4) which serves as a receptor for LPS, although the
potential role of TLR4 and associated cell signalling in controlling platelet responses to LPS
has not been extensively explored. In this study, we therefore investigated the actions of
LPS prepared from different strains of Escherichia coli on platelet function, the underlying
signalling mechanisms, and the potential role of TLR4 in orchestrating these. We report that
LPS increased the aggregation of washed platelets stimulated by thromboxane (U46619) or
GPVI collagen receptor agonists, effects that were prevented by a TLR4 antagonist. Associ-
ated with this, LPS enhanced fibrinogen binding, P-selectin exposure and reactive oxygen
species (ROS) release. Increase of ROS was found to be important for the actions of LPS
on platelets, since these were inhibited in the presence of superoxide dismutase or catalase.
The effects of LPS were associated with phosphorylation of Akt, ERK1/2 and PLA2 in stimu-
lated platelets, and inhibitors of PI3-kinase, Akt and ERK1/2 reduced significantly LPS
enhanced platelet function and associated ROS production. Furthermore, inhibition of plate-
let cyclooxygenase or the thromboxane receptor, revealed an important role for thrombox-
ane A2. We therefore conclude that LPS increases human platelet activation through a
TLR4-PI3K-Akt-ERK1/2-PLA2 -dependent pathway that is dependent on ROS and TXA2
formation.
Introduction
Platelets are required for haemostasis and respond to tissue injury to form an aggregate or
platelet plug that limits the loss of blood. Inappropriate activation of platelets in diseased blood
vessels is, however, a major trigger for thrombosis and platelets are increasingly implicated in
inflammation and the symptoms of sepsis [1]. Lipopolysaccharide (LPS) from the cell envelope
of Gram-negative bacteria is a principal cause of the symptoms of sepsis and this can result in
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platelet sequestration in the lungs and liver, thrombocytopenia and disseminated intravascular
coagulation (DIC) [2, 3]. LPS has been reported to modulate the function of platelets [4, 5, 6],
although the underlying mechanisms of LPS action remain unclear. Indeed, some studies have
indicated that exposure of platelets to LPS in vitro potentiates platelet function [7, 8], while
others have indicated that it supresses their activity [9]. Furthermore, LPS from different
sources and at distinct concentrations are able to promote variable effects in a range of cells
types [10,11].
LPS has been demonstrated to induce excessive secretion of pro-inflammatory mediators
such as cytokines, tumor necrosis factor alpha (TNFα) and reactive oxygen species (ROS) in
different cells [5, 12], and overproduction of ROS has been associated with damage to vascular
endothelium and multiple organ dysfunction [13]. Previous studies have suggested that stimu-
lated and unstimulated platelets are capable of releasing ROS that participate in the control of
platelet function [14, 15]. The mechanisms that lead the release of ROS by platelets are, how-
ever, incompletely understood.
Platelets, express the pathogen recognition receptor, Toll-like receptor 4 (TLR4) that serves
as a receptor for LPS on a range of cells types [3, 16, 17]. The role in platelets that this receptor
may play in stimulating the signalling that controls platelet responses to LPS has yet to be
explored. Therefore, in the present study we sought to explore the signalling pathway(s)
through which LPS modulates platelets regulation.
Ligation of TLR4 induces recruitment of multiple adaptor proteins such as TRIF, MyD88,
TIRAP, TRAM and SARM through interactions with Toll-interleukin-1 receptor domains
[18]. Previous studies have identified a number of proteins implicated in TRIF dependent sig-
nalling (eg. TBK-1, IRAK-1, JNKs, MAPK, TRAF3, TRAF6, IRF-3, Ikk-I, IκB-α, NK-κB) that
are present in platelets [7, 19, 20]. In vascular smooth muscle, LPS- mediated signalling pro-
motes activation of the mitogen-activated kinases (MAPKs) p38, ERK1/2 and JNK1/2 and also
the phosphoinositide- 3 kinase (PI3-kinase) dependent signalling [21]. Furthermore, Brown
and McIntyre showed that in platelets, MyD88, TRAF6, JNK and AKT are required in IL-1β
production stimulated by LPS [22].
Platelet activation by agonists such as collagen or thromboxane A2 is associated with the
activation of a complex network of cell signalling [23, 24] in which several molecules impli-
cated in TLR4 signalling are critically involved, including PI3-kinase (PI3K), Akt, and ERK1/2
[25, 26, 27]. While these signalling proteins have been shown to mediate some actions of LPS
on different cells [25, 26], their potential involvement in TLR4 signalling in platelets has not
been established.
The aim of this study was to elucidate whether components of the TLR4 signalling pathway
are implicated in the functional responses of platelets to LPS and the involvement of ROS pro-
duction in these responses. Here, we found that LPS increases human platelet activation
through a TLR4-PI3K-Akt-ERK1/2-PLA2-dependent pathway that is dependent on ROS and
TXA2 formation.
Materials and methods
Isolation and purification of Lipopolysaccharide from Gram-negative
bacteria
LPS from E. coli K12 was isolated and purified using methodology described by Davis and
Goldberg, 2012 [28]. The purity LPS samples prepared were visualized by direct staining fol-
lowing separation on 12% SDS-polyacrilamide gel using Pro-Q Emerald 300 Lipopolysaccha-
ride Gel Stain Kit (Sigma Aldrich, UK) (S1 Fig). LPS purified from E. coli O111:B4 was
purchased from Sigma Aldrich.
TLR4 potentiates platelet activation
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Platelet preparation
Blood was drawn from healthy donors that had given informed consent. The study and proce-
dures for obtaining informed consent were approved by the University of Reading Research
Ethics Committee. Blood was collected into 50mL syringes containing 4% (w/v) sodium citrate
and acid citrate dextrose (ACD, 2.5% sodium citrate, 2% D-glucose and 1.5% citric acid). Plate-
let preparation was according to the methodology developed previously to limit the levels of leu-
kocyte or erythrocyte contamination to no more than one contamination cell per 6500 platelets
[29]. The blood was centrifuged for 20 min at 102× g at room temperature to obtain platelet-
rich plasma (PRP). Further centrifugation of PRP [with 125 ngmL–1 prostaglandin I2 (PGI2)]
at 1413× g for 10 min resulted in a platelet pellet that was re-suspended in modified Tyrodes-
HEPES buffer (134 mM NaCl, 2.9 mM KCl, 0.34 mM Na2HPO412H2O, 12 mM NaHCO3, 20
mM HEPES and 1 mM MgCl2, pH 7.3) and washed by centrifuging in the presence of PGI2
again at the same speed for 10 min. The resulting platelet pellet was re-suspended in modified
Tyrodes-HEPES buffer to a final density of 4 × 108 cellsmL−1 for optical aggregometry, flow
cytometry and ROS release assays, and 8 × 108 cellsmL−1 for immunoblot analysis.
Aggregation
Platelet aggregation assays were performed by optical aggregometry stimulated with the throm-
boxane A2 receptor agonist U46619 (Cayman Chemical) or the collagen receptor glycoprotein
VI agonist, cross-linked collagen-related peptide (CRP-XL) (supplied by Prof R. Farndale, Uni-
versity of Cambridge, UK) [30]. Platelets were stimulated in this way in the presence or absence
of LPS from E. coli O111:B4 (Sigma Aldrich, UK) or from E. coli K12 (purified as described
above), superoxide dismutase (SOD, Sigma Aldrich, UK), catalase (Sigma Aldrich, UK), inhibi-
tor of PI3K- LY294002 (Selleckchem, UK), inhibitor of PI3K-δ- Cal (Selleckchem, UK), Akt
inhibitor IV (Calbiochem, UK), inhibitor of MEK- Cobimetinib (Selleckchem, UK), indometh-
acin (Sigma Aldrich, UK), the TXA2 receptor antagonist- GR32191 (Sigma Aldrich, UK), the
TLR4 antagonist- LPS RS ultrapure (InvivoGen, UK) or vehicle used to dissolve each of the
above (containing 0.01% (v/v) dimethyl sulphoxide, which did not affect platelet function, or
distilled water). Aggregation assays were performed with 250μL of washed platelet suspension
after incubation for 3 minutes with respective inhibitors followed by stimulation with agonist or
agonist plus LPS from Escherichia coli- K12 or from Escherichia coli- O111:B4 for 5 minutes.
Aggregation was monitored using Chrono-Log Model 700/ Optical-Lumi Aggregometer.
Immunobloting assay
SDS-PAGE and immunoblotting were performed using standard protocols as described previ-
ously [31]. Rabbit anti-human 14-3-3z (Santa Cruz Biotechnology, USA) was used to detect
14-3-3z to ensure equivalent levels of protein loading on immunoblots. The phospho-specific
antibodies against various signalling proteins (Akt, ERK1/2 and PLA2) were obtained from
Cell signalling technology, USA (catologue numbers: 9271, 4370 and 2831 respectively). The
secondary antibodies for immunoblotting; Cy5 goat anti-rabbit IgG and Cy3 goat anti-mouse
IgG antibodies were obtained from Invitrogen, UK. Blots were visualised using a Typhoon
FLA 9500 fluorimager (GE healthcare, UK). Image Quant TL software (GE Healthcare) was
used for the fluorescence visualisation and analysis of protein bands.
Alpha granule secretion and fibrinogen binding
Flow cytometric assays were performed in 96-well plates. U46619 or CRP-XL-stimulated
fibrinogen binding and P-selectin exposure were measured in PRP using FITC labelled rabbit
TLR4 potentiates platelet activation
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Fig 1. LPS potenciates U46619-stimulated platelet activation. Human-washed platelet aggregation was performed by optical
aggregometry following stimulation with U46619 (0.25μM) or CRP-XL (0.25μg/ml) in the presence or absence of LPS from E. coli
O111:B4 (0.5, 1, 5 or 7.5μg/mL) or LPS RS (1 or 7.5 μg/mL) (A, B, E, F). The effect of U46619 or CRP-XL and LPS- on fibrinogen
TLR4 potentiates platelet activation
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anti-human fibrinogen antibodies (Dako UK Ltd) and PE/Cy5 labelled mouse anti-human
anti-CD62P antibody (BD Biosciences, UK) respectively in the presence or absence of different
antagonists or inhibitors for 3 minutes prior to activation (e.g. superoxide dismutase- SOD,
catalase, inhibitor of PI3-Kinase- LY294002, inhibitor of PI3K-δ (Cal), Akt inhibitor IV, inhib-
itor of MEK (cobimetinib), Indomethacin, TXA2 antagonist (GR32191) or TLR4 antagonist
(LPS RS ultrapure) or vehicle (containing 0.01% dimethyl sulphoxide or distilled water)).
Platelets were stimulated with U46619 or CRP in the presence or absence of LPS from Escheri-
chia coli- O111:B4 or from Escherichia coli- K12 for 5 minutes at room temperature and then
fixed in 0.2% (v/v) formyl saline prior to analysis by BD Accuri flow cytometry (BD Biosci-
ences, Oxford, UK) equipped with a 488 nm wavelength argon laser, 510–540 nm band pass
filter. Data were acquired from 10000 cells and recorded as percentage of cells positive or
median fluorescence intensity (MFI).
Platelet ROS-production measured by flow cytometry
Production of ROS by platelets was measured by flow cytometry following the loading of plate-
lets with the fluorescent dye, 2’,7’-dichlorofluorescin diacetate (DCFH-DA) (Sigma Aldrich,
UK). DCFH is membrane-impermeable and rapidly oxidizes into the highly fluorescent 2´,7‘-
dichlorofluorescin (DCF) in the presence of intracellular hydrogen peroxide (H2O2), peroxy-
nitrite (ONOO-), peroxides and hydroxyl radicals (OH) [32]. Briefly, 50μL of washed platelets
(4 x 108/ml) were preincubated with 10μM DCFH-DA in the presence or absence of inhibitors
(e.g. superoxide dismutase, catalase, inhibitor of PI3-Kinase (LY294002), inhibitor of PI3K
(Cal), Akt inhibitor IV, inhibitor of MEK- (cobimetinib), indomethacin, TXA2 receptor antag-
onist (GR32191) or TLR4 antagonist (LPS RS ultrapure), or vehicle (containing 0.01% (v/v)
dimethyl sulphoxide) for 10 minutes at 37˚C in the dark in a 24 well plate before stimulation
with U46619 or CRP-XL, together with LPS from Escherichia coli- O111:B4 or LPS from
Escherichia coli- K12 for 10 minutes. The samples were then fixed with 200μL of sodium azide
(0.1% w/v) at room temperature for 10 minutes in the dark. Samples were analysed by BD
Accuri flow cytometry (BD Biosciences, Oxford, UK) equipped with a 488 nm wavelength
argon laser, 510–540 nm band pass filter. Data were acquired from 10000 cells and recorded as
percentage of cells positive or median fluorescence intensity (MFI).
Statistical analysis
Data are presented as mean ± standard deviation of the mean (SEM). Statistical analyses were
performed using PRISM 5 GRAPHPAD software (GraphPad Software Inc, La Jolla, CA, USA).
Data were analysed to confirm normal distribution and compared using a Student’s t-Test or
One-way ANOVA- and Bonferroni post-test analysis as appropriate.
Results
LPS in vitro potentiates activation of stimulated platelets
The effect of LPS on platelet function remains uncertain, although previous work has shown
that different preparations of LPS in vitro induce platelet aggregation [7, 33]. To analyse the
effects of LPS on platelet aggregation, washed human platelets were incubated with LPS from
E. coli O111:B4 or alternatively purified from E. coli K12 (0.5, 1, 5 or 7.5µg/mL) in the presence
binding and P-selectin exposure was measured in PRP by flow cytometry (C, D, G, H). Cumulative data represent mean values ± SEM
(n = 4). (Anova-Bonferroni test, * P 0.05; ** P 0.01; ***P 0.001).
https://doi.org/10.1371/journal.pone.0186981.g001
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or absence of the thromboxane receptor agonist U46619 (0.25μM) or the GPVI collagen recep-
tor agonist CRP-XL (0.25μg/mL) and analysed for 5 min in an optical aggregometer. Both
sources of LPS increased significantly the aggregation of platelets stimulated with U46619 (Fig
1A and 1B (LPS: E. coli O111:B4); S2A Fig (LPS: E. coli K12)) and CRP-XL Fig 1E and 1F (LPS:
E. coli O111:B4); S2E Fig (LPS: E. coli K12)) by 42% and 21% respectively. To confirm that the
effects of LPS on platelets were stimulated by binding to TLR4, LPS from Rhodobacter sphaer-
oides (LPS-RS) (1μg/mL), a TLR4 antagonist, was used. LPS-RS prevented the increase in
aggregation stimulated by LPS from E.coli O111:B4 in platelets stimulated with U46619 (Fig
1B) or CRP-XL (Fig 1F).
Platelet inside-out signalling leads to a conformational change in integrin αIIbβ3 convert-
ing it from a low to high affinity state, thereby allowing activation dependent binding of its
ligands fibrinogen and Von Willebrand Fator (VWF) [34]. This is also associated with the
secretion of α-granules which contain adhesion proteins such as fibrinogen, VWF, coagulation
and fibrinolytic factors [35]. To analyse the effects of LPS on the modulation of integrin
αIIbβ3 affinity and α-granule secretion, fibrinogen binding and P-selectin exposure on the
surface of platelets were measured by flow cytometry. Although both LPS from E. coli O111:B4
or the alternative LPS from E. coli K12 (1 and 7.5 μg/mL) caused a slight decrease in optical
density of platelet suspensions (5%), LPS from E. coli O111:B4 raised approximately two-fold
the level of fibrinogen binding and P-selectin exposure on unstimulated platelets. Following
stimulation with U46619 (Fig 1C and 1D (LPS: E. coli O111:B4)); S2B and S2C Fig (LPS: E. coli
K12)) or CRP-XL (Fig 1G and 1H (LPS: E. coli O111:B4); S2F and S2G Fig (LPS: E. coli K12)),
both source of LPS were able to significantly increase fibrinogen binding (LPS from E. coli
O111:B4: 70% and 200% respectively with U46619 and CRP-XL; LPS from E. coli K12: 170%
and 145% respectively with U46619 and CRP-XL) and P-selectin exposure (LPS from E. coli
O111:B4: 130% and 100% respectively with U46619 and CRP-XL; LPS from E. coli K12: 170%
and 120% respectively with U46619 and CRP-XL).
LPS potentiates aggregation through an increase of platelet-ROS
production
Platelets are widely recognised to contribute to inflammation and themselves can generate
endogenous inflammatory mediators and ROS [14, 15]. To investigate the capacity of LPS to
induce platelet ROS-generation by TLR4 binding and to explore the cell signalling that may
control this, ROS production was measured in stimulated and unstimulated platelets by flow
cytometry using the DCFH-DA fluorescent ROS probe (10μM). Stimulation of platelets with
U46619 was associated with an increase in platelet- derived ROS. Both sources of LPS (1 and
7.5 μg/mL) promoted approximately three-fold increase of ROS release in platelets stimulated
with U46619 (0.25μM) (Fig 2A and 2B (LPS: E. coli O111:B4); S2D Fig (LPS: E. coli K12). LPS
from E. coli O111:B4 and from E. coli K12 were able also to raise by approximately 70% the
ROS release of unstimulated platelets (Fig 2A (LPS: E. coli O111:B4 S2D and S2H Fig (LPS: E.
coli K12)). Incubation with TLR4 antagonist- LPS RS ultrapure decreased substantially the
Fig 2. ROS release induced by LPS promotes potentiation of aggregation. Washed platelets (4 x 108/ml)
were pre-incubated with 10μM DCFH-DA in the presence or absence of vehicle, LPS from E. coli O111:B4
(0.5 or 1μg/mL) or LPS RS (1μg/mL), superoxide dismutase- SOD (30U/mL) or catalase (300U/mL) before
being activated with U46619 (0.25μM). Samples were analysed by flow cytometry and the levels of ROS
released were detected and expressed as % increase above levels detected in unstimulated platelets (A and
B). Human-washed platelet aggregation was performed by optical aggregometry following stimulation with
U46619 (0.25μM) in the presence or absence of LPS from E. coli (1μg/mL) after 3 min of incubation with
superoxide dismutase- SOD (30U/mL) or catalase (300U/mL) (C). Cumulative data represent mean
values ± SEM (n = 4). (Anova-Bonferroni test, * P 0.05; Test t student # P 0.01; # # P 0.01).
https://doi.org/10.1371/journal.pone.0186981.g002
TLR4 potentiates platelet activation
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Fig 3. Exposure of platelets to LPS potentiates PI3K/Akt signalling. Washed human platelets with or without treatment with U46619
(0.25μM) in the presence or absence of LPS from E. coli O111:B4 (1μg/mL) were analysed by immunoblotting using antiphospho-Akt
TLR4 potentiates platelet activation
PLOS ONE | https://doi.org/10.1371/journal.pone.0186981 November 14, 2017 8 / 22
production of ROS raised by LPS from E. coli O111:B4 in platelets stimulated with U46619
(0.25μM, reduction of 60%) (Fig 2A), suggesting that LPS potentiates ROS generation in plate-
lets through TLR4 binding.
Platelet activation can be modulated by ROS derived from sources including stimulated
platelets themselves, such as superoxide anions (O-2) and hydrogen peroxide (H2O2) [36]. To
analyse whether LPS-potentiated platelet aggregation was associated with the modulation of
O-2 and H2O2 production, platelets were incubated with superoxide dismutase- SOD (30U/
mL) or catalase (300U/mL) (inhibitors of O-2 and H2O2 respectively), prior to being stimulated
with U46619 (0.25μM). Both SOD and catalase were able to reduce the LPS- E. coli O111:B4
-induced increases in aggregation and ROS generation to a similar level to that seen in the
absence of LPS (Fig 2B and 2C). These analyses indicate that H2O2 and O
-2 are likely to con-
tribute to the potentiation of aggregation mediated by LPS in vitro.
LPS potentiates platelets responses via PI3K/Akt signalling
Phosphoinositide 3-kinase (PI3K)/Akt-dependent signalling is involved in activation of integrin
αIIbβ3 and regulates platelet secretion [23]. Previous studies have shown the involvement of the
PI3K-Akt pathway in LPS-mediated effects in various cells [25, 26]. To assess the effect of LPS in
vitro on PI3K-Akt dependent signalling in platelets, we employed western blotting to measure
Akt phosphorylation on Ser 473. LPS (1μg/mL) raised by three-fold the phosphorylation of Akt in
platelets stimulated with U46619 (0.25μM) (Fig 3A). Platelets were incubated with a pan- PI3K
isoform inhibitor LY294002 (20μM), an inhibitor of PI3K-δ- Cal (60μM) or the Akt inhibitor IV
(5μM) and platelet function was measured. The increase of aggregation induced by LPS in plate-
lets stimulated with U46619 (0.25μM, (Fig 3B) or CRP-XL (0.25μg/mL, (S3A Fig)) was reduced
significantly by the three inhibitors (approximately 50% inhibition for LY294002 and 70% for
Cal or Akt inhibitor). Consistent with their effects on aggregation, the three inhibitors decreased
substantially fibrinogen binding and P-selectin exposure of platelets stimulated with U46619
(0.25μM) and LPS (1μg/mL) (Fig 3C and 3D). LY294002 and Cal reduced the increase of ROS
produced by LPS treatment to the level observed in the absence of LPS in platelets stimulated with
U46619 (Fig 3E), although CRP-XL-stimulated ROS production was not inhibited by these inhibi-
tors (S3B Fig). Together these data suggest that the PI3K/Akt pathway cooperates with LPS signal-
ling which promotes enhanced platelet activation through the release and actions of ROS.
Akt mediates LPS pathway through ERK1/2 and PLA2- phosphorylation
ERK activation plays an essential role in mediating platelet granule release by amplifying plate-
let responses and promoting a second wave of platelet aggregation [24]. It has previously been
suggested that cell signalling promoted through the binding of LPS with TLR4 involves ERK1/
2 phosphorylation and activation [31]. The ability of LPS (1μg/mL) to modulate ERK1/2 phos-
phorylation was therefore tested using immunoblot analysis. In stimulated platelets (U46619-
0.25μM), ERK1/2 phosphorylation was increased by a factor of three in the presence of LPS
(1μg/mL) (Fig 4A). The inhibitor of ERK1/2, Cobimetinib (100μM) reduced dramatically
(Ser473) antibody. Total levels of 14-3-3 ζwere measured on each sample as a loading control (A). Human-washed platelet aggregation
was performed by optical aggregometry activated with U46619 (0.25μM) in the presence or absence of LPS from E. coli O111:B4 (1μg/
mL) after 3 min of incubation with LY294002 (20μM), Cal (60μM) or Akt inhibitor IV (5μM) (B). The effect of U46619 and LPS- induced
fibrinogen binding and P-selectin exposure after incubation with LY294002 (20μM), Cal (60μM) or Akt inhibitor IV (5μM) were measure in
PRP by flow cytometry (C and D). Washed platelets (4 x 108/ml) were pre-incubated with 10μM DCFH-DA in the presence or absence of
LY294002 (20μM), Cal (60μM) or Akt inhibitor IV (5μM) before being activated with U46619 (0.25μM) in the presence or absence of LPS
from E. coli O111:B4 (1μg/mL) and ROS levels were analysed by flow cytometry (E). Cumulative data represent mean values ± SEM
(n = 4). (Anova-Bonferroni test, * P 0.05; ** P 0.01; ***P 0.001; Test t student # # P 0.01).
https://doi.org/10.1371/journal.pone.0186981.g003
TLR4 potentiates platelet activation
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(approximately 95%) the aggregation of platelets induced by U46619 (Fig 4B) or CRP-XL (S4A
Fig) in the presence or absence of LPS. Additionally, Cobimetinib did not significantly change
fibrinogen binding and P-selectin exposure in U46619-stimulated platelets but reduced by
65% both functions in platelets stimulated in the presence of LPS (Fig 4C and 4D). The inhibi-
tor of ERK1/2 was also able to decrease by 75% the rise of ROS production by LPS in platelets
stimulated with U46619 (Fig 4E) and CRP (S4B Fig).
Previous research has shown that phosphorylation of ERK1/2 is associated with PLA2 activ-
ity [37] and in platelets this link is poorly understood. Given the significant effect of ERK1/2
on LPS signalling in platelet function, PLA2 activation was explored. Through immunoblotting
we verified that platelets stimulated with U46619 (0.25μM) and LPS (1μg/mL) exhibited an
increase of PLA2 phosphorylation of approximately 2.3-fold compared with platelets in the
absence of LPS (Fig 5A and 5C). The TLR4 antagonist did not have any effect on PLA2 activa-
tion in platelets stimulated with U46619 but this antagonist was able to decrease PLA2 phos-
phorylation of platelets stimulated with U46619 and LPS to levels observed in the absence of
LPS (Fig 5A and 5C). Indeed, in platelets stimulated with U46619 plus LPS, TLR4 antagonist
reduced ERK1/2 phosphorylation to the levels observed in the absence of LPS (Fig 5A and 5B).
These data suggest that ERK1/2 and PLA2 contribute to platelet signalling stimulated by LPS.
In order to analyse the involvement of Akt on ERK1/2 and PLA2 in LPS treated platelets,
immunoblotting was performed with platelets stimulated by U46619 (0.25μM) in the presence
or absence of Akt inhibitor IV (5μM). ERK1/2 and PLA2 phosphorylation induced by LPS
were decreased to levels observed in absence of LPS by Akt inhibitor IV (Fig 5A–5C). These
data indicate the potential effect of Akt in mediating platelet signalling through ERK1/2 and
PLA2 activation.
LPS signalling is associated with TXA2 production
Thromboxane A2 (TXA2) has been suggested to contribute in the development of sepsis [38, 39]
and PLA2 activation may be expected to result in TXA2 production [40]. To determine whether
TXA2 is a downstream molecule involved in effects of TLR4 signalling in platelets, the cyclooxy-
genase inhibitor indomethacin (10μM) was incubated with washed platelets before activation
with U46619 (0.25μM) or CRP-XL (0.25μg/mL). Indomethacin decreased significantly the LPS
induced increase in platelet function: aggregation was reduced by 42% and 73% (in platelets stim-
ulated with U46619 and CRP-XL respectively (Fig 6A; S5A Fig); fibrinogen binding and P-selectin
exposure were reduced to levels seen in the absence of LPS (Fig 6B and 6C; S5B and S5C Fig);
ROS production was decreased by 55% (with both antagonists plus LPS) (Fig 6D; S5D Fig).
Consistent with this, the TXA2 receptor antagonist- GR32191 (100ng) prevented the poten-
tiation of aggregation induced by LPS in platelets stimulated with both U46619 (0.25μM, (Fig
6E)) or CRP-XL (0.25μg/ml, (S5E Fig)). The pre-incubation of platelets with GR32191 reduced
fibrinogen binding and P-selectin exposure to the levels observed in the absence of LPS (in
platelets stimulated with both agonists) (Fig 6F and 6G, S5F and S5G Fig). GR32191 also
Fig 4. The role of ERK1/2 in LPS-mediated platelet potentiation. Washed human platelets stimulated or not with U46619 (0.25μM)
in the presence or absence of LPS from E. coli O111:B4 (1μg/mL) were analysed by immunoblotting using antiphospho- ERK1/2
antibody. Total levels of 14-3-3 ζwere measured on each sample as a loading control (A). Human-washed platelet aggregation was
performed by optical aggregometry following stimulation with U46619 (0.25μM) in the presence or absence of LPS from E. coli O111:B4
(1μg/mL) after 3 min of incubation with Cobimetinib (100μM) before activation with U46619 (0.25μM) (B). The effect of U46619
(0.25μM) and LPS- induced fibrinogen binding and P-selectin exposure after incubation with Cobimetinib (100μM) were measured in
PRP by flow cytometry (C and D). Washed platelets (4 x 108/mL) were pre-incubated with 10μM DCFH-DA in the presence or absence
of Cobimetinib (100μM) before being activated with U46619 (0.25μM) in the presence or absence of LPS from E. coli O111:B4 (1μg/mL)
and ROS levels were analysed by flow cytometry (E). Cumulative data represent mean values ± SEM (n = 4). (Anova-Bonferroni test, *
P 0.05; ** P 0.01; ***P 0.001; Test t student # P 0.05; # #P 0.01).
https://doi.org/10.1371/journal.pone.0186981.g004
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Fig 5. LPS stimulates ERK1/2 and PLA2- phosphorylation via TLR4 and Akt. Washed human platelets were
incubated for 3 minutes with LPS RS (1μg/mL) or Akt inhibitor IV (5μM) before activation with U46619 (0.25μM)
in the presence or absence of vehicle or LPS from E. coli (1μg/mL) and were analysed by immunoblotting using
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decreased by approximately 70% ROS production in platelets stimulated by U46619 and
CRP-XL in the presence of LPS (Fig 6H; S5H Fig). Thus, these data indicate that the effects of
LPS are mediated via TXA2.
ROS released by LPS modulates ERK1/2 and PLA2- phosphorylation
We have demonstrated that LPS activates ERK1/2 and PLA2 in platelets. To examine the role
of ROS in modulating the activation of these enzymes, the levels of ERK1/2 and PLA2 phos-
phorylation in LPS-stimulated platelets were measured in the presence or absence of SOD or
catalase. SOD treatment prevented LPS-induced phosphorylation of both ERK1/2 and PLA2 in
platelets stimulated with U46619 (0.25μM), and catalase strongly inhibited ERK1/2 phosphor-
ylation (Fig 7A–7C).
Discussion
In the present work we have demonstrated that PI3K and Akt mediate an increase of platelet
activation by LPS in vitro via ERK1/2/PLA2 pathway and our data also suggest this mechanism
to involve TXA2 production and ROS release.
The treatment of platelets with LPS in vitro promoted platelet stimulation by inducing
fibrinogen binding and the secretion of α-granule contents, both important markers of platelet
activation. The action of LPS in platelets is a matter of some debate in the literature. The results
of our study are consistent with previous studies in which LPS-induced enhancement of plate-
let function was observed in vitro [7, 8]. We found LPS to induce P-selectin secretion and acti-
vation of fibrinogen in both stimulated and unstimulated platelets, as seen in previous studies
[7, 31]. We also confirmed that LPS in vitro enhanced aggregation of stimulated platelets, but
not in resting platelets, in agreement with the work of Zhang et al (2009) and Rivadeneyra et al
(2014) [7,8]. It is interesting that LPS alone did not induce substantial platelet activation, but it
had an additive effect with established platelets agonists. An important limitation of existing
literature in which the potential roles of LPS on platelets has been considered is that LPS
derived from different bacteria are used, and the purity and quality are rarely presented. This
is likely to explain some divergent results, including studies that suggest that LPS causes inhibi-
tion of platelet function following acute exposure in vitro. To overcome this action, in this
study we employed LPS from two different strains of E.coli and TLR4-antogonising LPS. Nota-
bly, LPS purified from the two E. coli strains exerted similar effects. In addition to releasing
classic inflammatory mediators, LPS promotes the generation of reactive oxygen and nitrogen
species (ROS and RNS) by a range of cell types [5, 12]. Reports indicate that ROS can modulate
the pathogenesis of sepsis through modulation of innate immune signalling and causing path-
ologic damage to cells and organs [13].
In this study we have shown that LPS promotes an increase in ROS release both in resting
and in stimulated platelets. Studies have shown that O2
- reduces the threshold for platelet acti-
vation to collagen [14]. In addition, Dong et al showed that catalase in vitro reduces the likeli-
hood of platelet dysfunction during LPS-induced sepsis [41]. In the present study, using SOD
and catalase, we demonstrated that reactive oxygen species, such as O2
- and H2O2 do indeed
contribute to enhancement of platelet function followed acute exposure to LPS.
The involvement of platelets in innate immune responses is partly due to the expression of
Toll-like receptors (TLRs). Each TLR responds to a different set of ligands or PAMPs
antiphospho- ERK1/2 (A and B) and antiphospho-PLA2 (A and C) antibodies. Total levels of 14-3-3ζwere
measured on each sample as a loading control. Cumulative data represent mean values ± SEM (n = 4). (Anova-
Bonferroni test, * P 0.05; ** P 0.01).
https://doi.org/10.1371/journal.pone.0186981.g005
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(pathogen-associated molecular patterns), lipids, lipoproteins, proteins or nucleic acids
derived from bacteria, viruses and fungi [42]. Although platelets express several TLR family
members [6], TLR2 and 4 have been most extensively studied because they recognise ligands
in Gram-positive and negative bacteria, respectively [19] and because platelets contribute sig-
nificantly to the pathophysiology of sepsis and are also involved in the high mortality levels
associated with this disease [1]. After engagement, each TLR triggers its own distinctive biolog-
ical response, which is specific for the PAMP recognized [6, 43]. Our study focused on the
mechanisms triggered by LPS from E. coli.
Although PI3-kinase/Akt-dependent signalling has been shown to mediate some effects
derived from LPS action in different cells [28, 29], it has not been established whether
TLR4 signalling involves PI3-kinase/Akt activation. Here, we demonstrate that LPS in vitro
increased Akt phosphorylation and the inhibitors of PI3K and Akt prevented the increase of
platelet function and ROS production induced by LPS. Beyond the PI3K/Akt pathway, LPS
stimulation also triggers the activation of small GTPases and the ERK, JNK and p38 MAPK
pathways [44]. Here we found that LPS promoted ERK1/2 phosphorylation. Additionally, our
findings demonstrated that TLR4 signals promote platelet stimulation and ROS release via
MAPK- ERK1/2, and that is regulated by PI3K/Akt. These data are consistent with previous
work in other cell types which showed PI3K/Akt and ERK1/2 to mediate a range of biological
effects [21, 45, 46].
The binding of platelet integrin αIIbβ3 to ligands such as fibrinogen and VWF during aggre-
gation/adhesion contributes to platelet thrombus formation by promoting the secretion of
internal granules and the stimulation of a secondary wave of aggregation, together with the
formation of membrane vesicles with procoagulant activities [47]. These result in the phos-
phorylation of tyrosine and serine/threonine residues of several proteins including ERK, myo-
sin light chain (MLC) and cytoplasmic phospholipase A2 (cPLA2) [48]. In this context, our
data show that in stimulated platelets, LPS increases PLA2 activation via the actions of Akt.
During activation by various agonists, platelets undergo a cascade of events that result in
the enzymatic metabolism of arachidonic acid (AA) [48]. AA is derived from the plasma mem-
brane by the action of PLA2, and undergoes further metabolism by COX and TXA2 synthase
to form eicosanoid products such as prostaglandins (PGs), thromboxane (TX), and other oxy-
genated derivatives [49]. One of the downstream consequences of TLR signalling is cyclooxy-
genase activation and the formation of pro-inflammatory cytokines. In the context of platelets
a notable prostaglandin produced by COX-1 is TXA2 [50]. Various studies have reported the
increased release of TXA2 in the liver [37] and kidneys [27] in endotoxemia. Here, we sought
to verify if TXA2 is associated with the in vitro effects of LPS in platelets. Indeed, our results
demonstrated that indomethacin, an inhibitor of COX-1 and GR32191, an antagonist of the
TXA2 receptor decreased the effect of LPS on platelet function. Our results suggest that TXA2
produced by platelets is necessary for effective LPS actions. Consistent with this, Nocella et al
shows that the effects of LPS are inhibited by a TXA2 antagonist [46]. Kassouf et al report that
thrombin-induced TXB2 formation (a stable TXA2 metabolite) in platelets is suppressed by
Fig 6. LPS- mediated platelet activation is associated with TXA2 production. Human-washed platelet aggregation was
performed by optical aggregometry following stimulation with U46619 (0.25μM) in the presence or absence of LPS from E. coli
O111:B4 (1g/mL) after 3 min of incubation with indomethacin (10μM) or GR32191 (100ng) (A and E). The effect of U46619
(0.25μM) and LPS- induced fibrinogen binding and P-selectin exposure after incubation with indomethacin (10μM) or GR32191
(100ng) were measure in PRP by flow cytometry (B, C, F and G). Washed platelets (4 x 108/mL) were pre-incubated with 10μM
DCFHDA in the presence or absence of Indomethacin (10μM) or GR32191 (100ng) before being activated with U46619
(0.25μM) in the presence or absence of LPS from E. coli O111:B4 (1μg/mL) and ROS levels were analysed by flow cytometry
(D and H). Cumulative data represent mean values ± SEM (n = 4). (Anova-Bonferroni test, * P 0.05; ** P 0.01; ***P
0.001; Test t student # P 0.05; # # P 0.01; # # # P 0.001).
https://doi.org/10.1371/journal.pone.0186981.g006
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Akt inhibitor IV [51]. Here we propose that the pathway PI3K/Akt/ERK1/2/PLA2 leads to
TXA2 formation following the exposure of platelets to LPS.
Gram-negative pathogens such as E.coli induce platelet hyperactivity and ROS release,
which may add to the potentiation of the risk of vascular pathology. ROS can modulate
LPS-TLR4 signalling at different levels and promote an increase of consecutive stimuli in
immune cell [52]. Indeed, our results demonstrate that SOD was able to reduce ERK1/2 and
PLA2 phosphorylation and catalase reduced ERK1/2 activation, showing that ROS release acts
to modulate the signalling pathway following the binding of LPS to TLR4.
The involvement of PI3K, Akt and MAPK in the stimulation of platelets by agonists is
established. In this work we showed that LPS in vitro promotes an increase of platelet function
via proteins associated with the activation of platelets including Akt, ERK and PLA2. The
effects of LPS in vivo are likely to be more complex, since the range of cytokines released by
platelets and other cells, such as TNFα, interleukins and TGFβ may result in a systemic inflam-
matory state [53, 54, 55].
Disseminated intravascular coagulation associated with sepsis is present in approximately
35% of severe cases, developing to microvascular dysfunction and death [56]. Platelet activa-
tion is an essential event involved in the pathophysiological processes of the coagulation sys-
tem during sepsis [57]. PLA2 inhibitors have gained particular attention since this enzyme is
activated during inflammatory events and its expression is increased in several diseases [58]
including septic shock [59]. In equine platelets and leukocytes, LPS stimulation in vivo
increases TXA2 production and p38 MAPK phosphorylation to levels similar that reported in
clinical endotoxaemia [60]. Additionally, a study performed ex vivo has reported that LPS
stimulation of TLR4 potentiates platelet activation and TXA2 production in patients with com-
munity-acquired pneumonia [46]. The impact of increase secretion of factors from platelets
and endothelial cells in response to LPS is also likely to have complex effects on homeostasis
and potentially thrombosis, with some factors enhancing this, while others such as thrombo-
modulim, serving to inhibit coagulation [61].
In summary, our findings demonstrate that TLR4 triggered by acute exposure of platelets to
LPS promotes platelet stimulation via ERK1/2 and PLA2 activation and that is co-ordinately
regulated by PI3K/Akt, and provide evidence that this signalling pathway involves TXA2 pro-
duction and ROS generation.
Supporting information
S1 Fig. Analysis of lipopolysaccharides by polyacrilamide gel electrophoresis. LPS standard
from E. coli serotype 055:B5 and LPS from E. coli K12 were separated by 12% acrylamide gel
electrophoresis and stained using Pro-Q Emerald 300 Lipopolysaccharide Gel Stain Kit.
(TIF)
S2 Fig. Effect of LPS from E.coli K12 on human platelet activation. Human-washed platelet
aggregation was performed by optical aggregometry following stimulation with U46619
(0.25μM) or CRP-XL (0.25μg/mL) in the presence or absence of LPS from E.coli K12 (1 or
7.5μg/mL) (A and E). The effects of U46619 (0.25μM) or CRP (0.25μg/mL) and LPS on fibrin-
ogen binding and P-selectin exposure were measured in PRP by flow cytometry (B, C, F and
Fig 7. LPS induced ROS modulates ERK1/2 and PLA2 phosphorylation. Washed human platelets were incubated for
3 minutes with SOD (30U/mL) or catalase (300U/mL) before activation with U46619 (0.25μM) in the presence or absence
of vehicle or LPS from E. coli O111:B4 (1μg/mL) and were analysed by immunoblotting using antiphospho- ERK1/2 (A
and B) or antiphospho-PLA2 (A and C) antibodies. Total levels of 14-3-3ζwere measured on each sample as a loading
control. Cumulative data represent mean values ± SEM (n = 4). (Anova-Bonferroni test, * P 0.05; ***P 0.001).
https://doi.org/10.1371/journal.pone.0186981.g007
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G). Washed platelets (4 x 108/mL) were pre-incubated with 10μM DCFHDA before being acti-
vated with U46619 (0.25μM) or CRP-XL (0.25μg/mL) in the presence or absence of LPS from
E.coli K12 (1 or 7.5μg/mL) and ROS levels were analysed by flow cytometry (D and H). Cumu-
lative data represent mean values ± SEM (n = 4). (Anova-Bonferroni test,  P 0.05;  P
0.01;  P 0.001; Test t student # P 0.05).
(TIF)
S3 Fig. LPS potentiates activation of platelets stimulated by CRP via the PI3K/Akt path-
way. Human-washed platelet aggregation was performed by optical aggregometry activated
with CRP-XL (0.25μg/mL) in the presence or absence of LPS (7.5μg/mL) after 3 min of incuba-
tion with LY294002 (20μM), Cal (60μM) or Akt inhibitor IV (5μM) (A). Washed platelets (4 x
108/mL) were pre-incubated with 10μM DCFH-DA in the presence or absence of LY294002
(20μM), Cal (60μM) or Akt inhibitor IV (5μM) before being activated with CRP-XL (0.25μg/
mL) in the presence or absence of LPS from E. coli O111:B4 (7.5μg/mL) and ROS levels were
analysed by flow cytometry. Cumulative data represent mean values ± SEM (n = 4). (Anova-
Bonferroni test,  P 0.05;  P 0.01;  P 0.001; Test t student # P 0.05).
(TIF)
S4 Fig. LPS signalling pathway requires ERK1/2 in CRP-stimulated platelets. Aggregation
of human washed platelet was measured by optical aggregometry following stimulation with
CRP-XL (0.25μg/mL) in the presence or absence of LPS from E. coli O111:B4 (7.5μg/mL) after
3 min of incubation with Cobimetinib (100μM) (A). Washed platelets (4 x 108/mL) were pre-
incubated with DCFH-DA (10μM) in the presence or absence of Cobimetinib (100μM) before
being activated with CRP-XL (0.25μg/mL) in the presence or absence of LPS from E. coli
O111:B4 (7.5μg/mL) and ROS levels were analysed by flow cytometry. Cumulative data repre-
sent mean values ± SEM (n = 4). (Anova-Bonferroni test,  P 0.01;  P 0.001; Test t stu-
dent # # P 0.01).
(TIF)
S5 Fig. LPS-mediated platelet activation is associated with TXA2 production. Aggregation
of human washed platelet was measured by optical aggregometry following stimulation with
CRP-XL (0.25μg/mL) in the presence or absence of LPS from E. coli O111:B4 (7.5g/mL) after 3
min of incubation with Indomethacin (10μM) or GR32191 (100ng) (A and E). The effect of
CRP-XL (0.25μg/ml) and LPS- on fibrinogen binding and P-selectin exposure after incubation
with indomethacin (10μM) or GR32191 (100ng) were measure in PRP by flow cytometry (B,
C, F and G). Washed platelets (4 x 108/mL) were pre-incubated with DCFHDA (10μM) in the
presence or absence of Indomethacin (10μM) or GR32191 (100ng) before being stimulated
with CRP-XL (0.25μg/ml) in the presence or absence of LPS from E. coli O111:B4 (7.5μg/mL)
and ROS levels were analysed by flow cytometry (D and H). Cumulative data represent mean
values ± SEM (n = 4). (Anova-Bonferroni test,  P 0.05;  P 0.01;  P 0.001; Test t stu-
dent # P 0.05; # # # P 0.001).
(TIF)
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